Suven Life Sciences has received four product patents from different countries for its new chemical entities (NCEs) which could be used in treating various central nervous system disorders.
“The four product patents, one from New Zealand, one from Australia, one from Korea and one from Europe are.....valid through 2025,” the company said in a filing to the Bombay Stock Exchange.
The company has received the approval for molecules which could be used in the treatment of CNS disorders like Parkinsons, Alzheimers and Schizophrenia, it added.
Products out of these inventions may be out-licensed at various phases of clinical research like at phase I or phase II, the company said.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which have an estimated $30-billion market potential globally,” the company CEO, Mr Venkat Jasti, said.
With these new patents, the company now has eight patents from Europe, ten from New Zealand, nine from Australia and three from Korea for the NCEs, it said.
Meanwhile, the shares of Suven Life Sciences were trading at Rs 21.05 in the afternoon trade on the BSE today, up 4.99 per cent from its previous close. PTI AKT MSS TVS 05261338